133 related articles for article (PubMed ID: 34762175)
1. Indications for conversion hepatectomy for initially unresectable colorectal cancer with liver metastasis.
Sugiyama M; Uehara H; Shin Y; Shiokawa K; Fujimoto Y; Mano Y; Komoda M; Nakashima Y; Sugimachi K; Yamamoto M; Morita M; Toh Y
Surg Today; 2022 Apr; 52(4):633-642. PubMed ID: 34762175
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival.
Beppu T; Miyamoto Y; Sakamoto Y; Imai K; Nitta H; Hayashi H; Chikamoto A; Watanabe M; Ishiko T; Baba H
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S405-13. PubMed ID: 24570379
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Outcomes of Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastases.
Maeda Y; Shinohara T; Nagatsu A; Futakawa N; Hamada T
Ann Surg Oncol; 2016 Feb; 23 Suppl 2():S242-8. PubMed ID: 25749931
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases.
Kawamura J; Yazawa T; Sumida K; Kida Y; Ogawa R; Tani M; Kawasoe J; Yamamoto M; Harada H; Yamamoto H; Zaima M
World J Surg Oncol; 2016 Feb; 14():56. PubMed ID: 26911142
[TBL] [Abstract][Full Text] [Related]
5. Predictors for early recurrence after hepatectomy for initially unresectable colorectal liver metastasis.
Takahashi S; Konishi M; Kinoshita T; Gotohda N; Kato Y; Saito N; Sugito M; Yoshino T
J Gastrointest Surg; 2013 May; 17(5):939-48. PubMed ID: 23400510
[TBL] [Abstract][Full Text] [Related]
6. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-RAS status for unresectable colorectal liver metastasis (BECK study): Long-term results of survival.
Okuno M; Hatano E; Toda R; Nishino H; Nakamura K; Ishii T; Seo S; Taura K; Yasuchika K; Yazawa T; Zaima M; Kanazawa A; Terajima H; Kaihara S; Adachi Y; Inoue N; Furumoto K; Manaka D; Tokuka A; Furuyama H; Doi K; Hirose T; Horimatsu T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S
J Hepatobiliary Pancreat Sci; 2020 Aug; 27(8):496-509. PubMed ID: 32362018
[TBL] [Abstract][Full Text] [Related]
7. Type of response to conversion chemotherapy strongly impacts survival after hepatectomy for initially unresectable colorectal liver metastases.
Zimmitti G; Panettieri E; Ardito F; Rosso E; Mele C; Nuzzo G; Giuliante F
ANZ J Surg; 2020 Apr; 90(4):558-563. PubMed ID: 31927783
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic factors affecting the success of conversion chemotherapy in patients with unresectable liver metastases from initially colorectal cancer].
Zhang WL; Zhou C; Deng YX; Hou ZL; Zhang LJ; Lin JZ; Pan ZZ; Lu ZH; Peng JH
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jan; 25(1):56-62. PubMed ID: 35067035
[No Abstract] [Full Text] [Related]
9. Liver transplantation in a patient with unresectable colorectal liver metastases -- a case report.
Hrehoreţ D; Alexandrescu S; Braşoveanu V; Grigorie R; Zielinski C; Popescu I
Chirurgia (Bucur); 2013; 108(5):719-24. PubMed ID: 24157119
[TBL] [Abstract][Full Text] [Related]
10. Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease?
Kataoka K; Kanazawa A; Iwamoto S; Kato T; Nakajima A; Arimoto A
World J Surg; 2014 Apr; 38(4):936-46. PubMed ID: 24166026
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
DʼAngelica MI; Correa-Gallego C; Paty PB; Cercek A; Gewirtz AN; Chou JF; Capanu M; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N
Ann Surg; 2015 Feb; 261(2):353-60. PubMed ID: 24646562
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the selection of technically unresectable colorectal liver metastases.
Kobayashi K; Inoue Y; Kitano Y; Sato S; Oba A; Ono Y; Sato T; Ito H; Mise Y; Saiura A; Takahashi Y
Surgery; 2023 Feb; 173(2):442-449. PubMed ID: 36384649
[TBL] [Abstract][Full Text] [Related]
14. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
Hatano E; Okuno M; Nakamura K; Ishii T; Seo S; Taura K; Yasuchika K; Yazawa T; Zaima M; Kanazawa A; Terajima H; Kaihara S; Adachi Y; Inoue N; Furumoto K; Manaka D; Tokka A; Furuyama H; Doi K; Hirose T; Horimatsu T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):634-45. PubMed ID: 25926024
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases.
Lam VW; Spiro C; Laurence JM; Johnston E; Hollands MJ; Pleass HC; Richardson AJ
Ann Surg Oncol; 2012 Apr; 19(4):1292-301. PubMed ID: 21922338
[TBL] [Abstract][Full Text] [Related]
16. Does response rate of chemotherapy with molecular target agents correlate with the conversion rate and survival in patients with unresectable colorectal liver metastases?: A systematic review.
Okuno M; Hatano E; Nishino H; Seo S; Taura K; Uemoto S
Eur J Surg Oncol; 2017 Jun; 43(6):1003-1012. PubMed ID: 27624917
[TBL] [Abstract][Full Text] [Related]
17. Conversion to Resection in Patients Receiving Systemic Chemotherapy for Unresectable and/or Metastatic Colorectal Cancer-Predictive Factors and Prognosis.
Nozawa H; Ishihara S; Kawai K; Hata K; Kiyomatsu T; Tanaka T; Nishikawa T; Otani K; Yasuda K; Sasaki K; Kaneko M; Murono K
Clin Colorectal Cancer; 2018 Mar; 17(1):e91-e97. PubMed ID: 29113730
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of the liver-first approach for patients with initially unresectable and not optimally resectable synchronous colorectal liver metastases.
Okuno M; Hatano E; Kasai Y; Nishio T; Seo S; Taura K; Yasuchika K; Nitta T; Mori A; Okajima H; Kaido T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S
Surg Today; 2016 Jun; 46(6):721-8. PubMed ID: 26315324
[TBL] [Abstract][Full Text] [Related]
19. Hepatectomy for liver metastases in non-colorectal, non-neuroendocrine cancer patients. The survival benefit in primary unresectable cases.
Maeda Y; Shinohara T; Katayama T; Futakawa N; Hamada T
Int J Surg; 2015 Oct; 22():136-42. PubMed ID: 26277530
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and potential benefit of preoperative chemotherapy for colorectal liver metastasis (CLM): a single-centered retrospective study.
Kataoka K; Kanazawa A; Nakajima A; Yamaguchi A; Arimoto A; Kohno Y
Surg Today; 2013 Oct; 43(10):1154-61. PubMed ID: 23139049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
